Scarica l'app Stockscreener
2.37
9.22%
0.20
Dopo l'orario di chiusura:
2.28
-0.09
-3.80%
Tharimmune Inc Borsa (THAR) Ultime notizie
What's Going On With Tharimmune Shares Monday? - Benzinga
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - Brazosport Facts
Tharimmune's Liver Drug Shows 33% Itch Reduction in Phase 1 Trial, Phase 2 Planned | THAR Stock News - StockTitan
Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock - Investing.com India
Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock By Investing.com - Investing.com Canada
What's Going On With Tharimmune Shares Wednesday? - MSN
Tharimmune set to receive European patent for cancer therapy tech - Investing.com
Tharimmune set to receive European patent for cancer therapy tech By Investing.com - Investing.com UK
Tharimmune Secures Key European Patent for Revolutionary Nanoparticle Drug Delivery System | THAR Stock News - StockTitan
Tharimmune Announces Upcoming Conference Presentations - StockTitan
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
Dow Surges Over 150 Points; Alphabet Posts Upbeat Results - MSN
United States shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
S&P 500 Edges Lower; US Crude Oil Inventories Fall - MSN
New Jersey-Based Biotech Company Finds Massive Mid-Week Success Following "Positive Feedback" - MSN
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast - Benzinga
S&P 500 Total Return (TCU24) Quote - The Globe and Mail
Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Coversee more stocks inside... - openPR
Tharimmune (THAR) Stock Rallies After Positive EMA Feedback Boosts Confidence - Stocks Telegraph
Tharimmune receives regulatory feedback from EMA for TH104 program - TipRanks
Tharimmune secures EMA feedback on pruritus drug trial - Investing.com
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis - StockTitan
Tharimmune Inc (THAR-Q) QuotePress Release - The Globe and Mail
TH104 trial shows promise for liver disease-related itch relief By Investing.com - Investing.com South Africa
TH104 trial shows promise for liver disease-related itch relief - Investing.com
Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting - TipRanks
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - Milton Daily Standard
Tharimmune CEO Randy Milby buys $5.2k in company stock - Investing.com India
Tharimmune CEO Randy Milby buys $5.2k in company stock By Investing.com - Investing.com Australia
Tharimmune COO acquires $9,650 in company stock - Investing.com
Tharimmune COO acquires $9,650 in company stock By Investing.com - Investing.com UK
Biohaven aims to raise $250M; Activist investor’s stake in Galapagos exceeds 10% - Endpoints News
Tharimmune Announces Intent to Acquire Intract Pharma - TipRanks
Tharimmune signs nonbinding LOI to merge with Intract Pharma - TipRanks
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company - StockTitan
Hillstream Biopharma stock plunges to 52-week low of $2.52 - Investing.com India
Tharimmune Expands Immunology Pipeline with Intract License - TipRanks
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab - StockTitan
Tharimmune, Inc. (NASDAQ:THAR) Short Interest Down 35.7% in July - Defense World
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory BoardChannel3000.com - Channel3000.com - WISC-TV3
Tharimmune adds David Clarke as Strategic Advisor - Investing.com
Tharimmune launches new website amid continuing discussions wtih FDA - TipRanks
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor - StockTitan
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104 - StockTitan
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):